Publikationen
Originalarbeiten
Ruxolitinib exposure in patients with acute and chronic graft versus host disease in routine clinical practice – a prospective single-center trial
Isberner, N., Kraus, S., Grigoleit, G.U., Aghai, F., Kurlbaum, M., Zimmermann, S., Klinker, H., Scherf-Clavel, O.
Cancer Chemotherapy and Pharmacology (2021), in press
doi: 10.1007/s00280-021-04351-w
The nitrosamine contamination of drugs, part 3: Quantification of 4-Methyl-1-nitrosopiperazine in rifampicin capsules by LC-MS/HRMS
Wohlfart J., Scherf-Clavel O., Kinzig M., Sörgel F., Holzgrabe U.
Journal of Pharmaceutical and Biomedical Analysis. (2021) 203:114205.
doi: 10.1016/j.jpba.2021.114205
Determination of Guanfacine in Oral Fluid and Serum of Children and Adolescents With Attention-Deficit/Hyperactivity Disorder: A Short Communication
Wohkittel, C., Scherf-Clavel, O., Fekete, S., Romanos, M., Högger, P., Gerlach, M.
Therapeutic Drug Monitoring (2021), in press
doi: 10.1097/FTD.0000000000000917
Simulation-based interpretation of therapeutically monitored cabozantinib plasma concentration in advanced adrenocortical carcinoma with hemodialysis
Zimmermann, S., Kurlbaum, M., Mayer, S., Fassnacht, M., Kroiss, M., Scherf-Clavel, O.
Therapeutic Drug Monitoring (2021), Volume 43, 706
doi: 10.1097/FTD.0000000000000905
Physiologically Based Pharmacokinetic Modelling of Cabozantinib to Simulate Enterohepatic Recirculation, Drug–Drug Interaction with Rifampin and Liver Impairment
Gerner, B., Scherf-Clavel, O.
Pharmaceutics (2021), Volume 13, 778
doi: 10.3390/pharmaceutics13060778
Investigation of isomerization of dexibuprofen in a ball mill using chiral capillary electrophoresis.
Urlaub, J., Kaiser, R.P., Scherf‐Clavel, O., Bolm, C., Holzgrabe, U.
Electrophoresis (2021), Volume 42, 1790
doi: 10.1002/elps.202000307
Development and validation of a sensitive liquid chromatography tandem mass spectrometry assay for the simultaneous determination of ten kinase inhibitors in human serum and plasma.
Aghai, F., Zimmermann, S., Kurlbaum, M., Jung, P., Pelzer, T., Klinker, H., Isberner, N., Scherf-Clavel, O.
Anal Bioanal Chemistry, (2020)
doi: 10.1007/s00216-020-03031-7
Objective response and prolonged disease control of advanced adrenocortical carcinoma with cabozantinib
Kroiss, M., Megerle, F., Kurlbaum, M., Zimmermann, S., Wendler, J., Jimenez, C., Lapa, c., Quinkler, M., Scherf-Clavel, O., Amir Habra, M., Fassnacht, M.
J Clin Endo Metab, (2020), Volume 105, 1461-1468
doi: 10.1210/clinem/dgz318
Glycerolipid Composition and Advanced Physicochemical Considerations of Sacha Inchi Oil toward Cosmetic Products Formulation
Penagos-Calvete D.,Duque, V, Marimon, C., Parra ,D. M., Restrepo-Arango, S. K., Scherf-Clavel, O., Holzgrabe, U., Montoya G., Salamanca C. H.
Cosmetics, (2019), Volume 6
doi: 10.3390/cosmetics6040070
Quantification of adefovir and pitavastatin in human plasma and urine by LC-MS/MS: A useful tool for drug-drug interaction studies
Scherf-Clavel, O., Kinzig, M., Stoffel, M.S., Fuhr, U., Sörgel, F.
J Chromatogr B, (2019), Volume 1125, 121718
doi: 10.1016/j.jchromb.2019.121718
A HILIC-MS/MS assay for the quantification of metformin and sitagliptin in human plasma and urine: A tool for studying drug transporter perturbation
Scherf-Clavel, O., Kinzig, M., Stoffel, M.S., Fuhr, U., Sörgel, F.
J Pharm Biomed Anal, (2019), Volume 175, 112754
doi: 10.1016/j.jpba.2019.07.002
A Clinical DDI Study Assessing a Novel Drug Transporter Phenotyping Cocktail with Adefovir, Sitagliptin, Metformin, Pitavastatin and Digoxin
Trueck, C., Hsin, C.H., Scherf-Clavel, O., Schaeffler, E., Lenssen, R., Gazzaz, M., Gersie, M., Taubert, M., Quasdorff, M., Schwab, M., Kinzig, M., Sörgel, F., Stoffel, M., Fuhr, U.
Clinical Pharmacology and Therapeutics, (2019), Volume 106, Pages 1398-1407
doi: 10.1002/cpt.1564
Determination of hydroxybupropion in human serum for routine therapeutic drug monitoring in psychiatry: a tool for dose-individualization in the treatment with bupropion
Scherf-Clavel, M., Wahl, O., Menke, A., Unterecker, S.
Biomed Chrom, (2019), Volume 33, e4609
doi: 10.1002/bmc.4609
A method for the minimally invasive drug monitoring of mitotane by means of volumetric absorptive microsampling for a home-based therapeutic drug monitoring
Friedl, B., Kurlbaum, M., Kroiss, M., Fassnacht, M., Scherf-Clavel, O.
Anal and Bioanal Chem (2019), Volume 411, (2019) Pages 3951-3962
doi: 10.1007/s00216-019-01868-1
The contamination of valsartan and other sartans, part 1: New findings
Sörgel, F., Kinzig, M., Abdel-Tawab, M., Bidmon, C., Schreiber, A., Ermel, S., Wohlfart, J., Besa, A., Scherf-Clavel, O., Holzgrabe, U.
J Pharm Biomed Anal (2019), Volume 172, (2019) Pages 278-284
doi: 10.1016/j.jpba.2019.05.022
The contamination of valsartan and other sartans, Part 2: Untargeted screening reveals contamination with amides additionally to known nitrosamine impurities
Scherf-Clavel, O., Kinzig, M., Besa, A., Schreiber, A.,Bidmon, C., Abdel-Tawab, M., Wohlfart, J., Sörgel, F., Holzgrabe, U.
J Pharm Biomed Anal, Volume 172 (2019), Pages 278-284
doi: 10.1016/j.jpba.2019.04.035
Development and validation of a new UHPLC method for related proteins in insulin and insulin analogues as an alternative to the European Pharmacopoeia RP-HPLC method
Wahl, O., Jorajuria, S.
J Pharm Biomed Anal (2018), Volume 166, (2019), Pages 71-82
doi:10.1016/j.jpba.2018.12.034
Impurity profiling of N,N′-ethylenebis-l-cysteine diethyl ester (Bicisate)
Wahl, O., Cleynhens, J., Verbruggen, A., Holzgrabe, U.
J Pharm Biomed Anal, Volume 150C (2018), Pages 132 – 136
doi:10.1016/j.jpba.2017.11.078
Quantification of Hydrochlorothiazide and Ramipril/Ramiprilate in Blood Serum and Cerebrospinal Fluid: A Pharmacokinetic Assessment of Central Nervous System Adverse Effects
Sigaroudi, A., Kinzig, M., Wahl, O., Stelzer, C., Schroeter, M., Fuhr, U., Holzgrabe, U., Sörgel, F.
Pharmacology, Volume 102 (2018), Pages 133 – 137
doi.org/10.1159/000489999
Quantification of Bisoprolol and Metoprolol in Simultaneous Human Serum and Cerebrospinal Fluid Samples.
Sigaroudi, A., Kinzig, M., Wahl, O., Stelzer, C., Schroeter, M., Fuhr, U., Holzgrabe, U., Sörgel, F.,
Pharmacology, Volume 101 (2018), Pages 29 – 34
doi:10.1159/000480091
Impurity Profiling of Ibandronate sodium by HPLC-CAD.
Wahl, O., Holzgrabe, U.
J Pharm Biomed Anal, Volume 114 (2015), Pages 254 – 264doi:10.1016/j.jpba.2015.06.002
Evaluation of Enantiomeric Purity of Magnesium-L-aspartate Dihydrate.
Wahl, O., Holzgrabe, U.
J Pharm Biomed Anal, Volume 102 (2015), Pages 100 – 109doi:10.1016/j.jpba.2014.08.013
Impurity Profiling of Carbocisteine by HPLC-CAD, qNMR and UV/vis Spectroscopy.
Wahl, O., Holzgrabe, U.
J Pharm Biomed Anal, Volume 95 (2014), Pages 1 – 10 doi:10.1016/j.jpba.2014.02.012
Übersichtsartikel
The Challenging Pharmacokinetics of Mitotane: An Old Drug in Need of New Packaging
Haider, M.S., Ahmad, T., Groll, J., Scherf-Clavel, O., Kroiss, M., Luxenhofer, R.
Eur J Drug Metabol Pharmacokin (2021), in press
doi: 10.1007/s13318-021-00700-5
Drug-Drug Interactions with OTC medicines: Mind the unprescribed
Scherf-Clavel, O.
Therapeutic Drug Monitoring (2021), in press
doi: 10.1097/FTD.0000000000000924
Therapeutic drug monitoring of oral targeted antineoplastic drugs.
Mueller-Schoell, A., Groenland, S., Scherf-Clavel, O., Van Dyk, M., Huisinga, W., Michelet, R., Jaehde, U., Steeghs, N., Huitema, A.D.R., Kloft, C.
Eur J Clin Pharmacol (2020)
doi: 10.1007/s00228-020-03014-8
Amino Acid Analysis for Pharmacopoeial Purposes.
Wahl, O., Holzgrabe, U.
Talanta, Volume 154 (2016), Pages 150 – 163;
doi:10.1016/j.talanta.2016.03.071
Inhibition of Tumor Angiogenesis by Antibodies, Synthetic Small Molecules and Natural Products.
Wahl, O., Oswald, M., Tretzel, L., Herres, E., Arend, J., Efferth, T.
Curr Med Chem, Volume 18 (2011), Pages 3136 – 3155
doi: 10.2174/092986711796391570
Weitere
Pharmacokinetics of remdesivir in a COVID-19 patient with end-stage renal disease on intermittent hemodialysis
Sörgel, F., Malin, J.J., Hagmann, H., Kinzig, M., Bilal, M., Eichenauer, D.A., Scherf-Clavel, O., Simonis, A., El Tabei, L., Fuhr, U., Rybniker, J.
J Antimicrob Chemother, (2020)
doi: 10.1093/jac/dkaa500
CaboACC: Cabozantinib beim fortgeschrittenen Nebennierenkarzinom nach Versagen der Standardtherapie / CaboACC: Cabozantinib in advanced adrenocortical carcinoma after failure of standard therapy
Kroiß M., Goebeler, M.E., Röser, C., Zimmermann, S., Landwehr, L., Scherf-Clavel, O., Malzahn, U., Kurlbaum, M., Faßnacht, M.
Forum, Sektion B – Klinische Studien, in press (2019)
doi: 10.1007/s12312-019-0632-3